Shopping Cart 0
Cart Subtotal
AED 0

Riemser Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

Riemser Pharma GmbH (Riemser), formerly Riemser Arzneimittel AG is a distributor of lifecycle management products. The company offers analgesics products, cardiovascular products, over-the-counter medicines, prescription drugs and dental products. It provides medical products for the treatment of infectious diseases, obesity, rheumatology, tuberculosis therapy, neurology, oncology and dermatological disorders such as psoriasis, acromycosis, acne, and herpes. Riemser also offers nutritional supplements. The company has research and development alliances with research institutes, universities, colleges and hospitals across Europe. It has operations in Germany, France and the UK. Riemser is headquartered in Greifswald, Germany.

Riemser Pharma GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Riemser Pharma Acquires European Rights to Prialt from Eisai 12

Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13

RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14

Private Equity 15

Ardian May Sell Riemser Pharma for USD494.3 Million 15

AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17

Asset Transactions 19

Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19

Acquisition 20

Riemser Pharma to Acquire Intrapharm Labs 20

Riemser Pharma Acquires Keocyt 21

Riemser Arzneimittel To Acquire 49% Stake In anwerina 22

Riemser Pharma GmbH-Key Competitors 23

Riemser Pharma GmbH-Key Employees 24

Riemser Pharma GmbH-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Appendix 26

Methodology 26

About GlobalData 26

Contact Us 26

Disclaimer 26


List Of Figure

List of Figures

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Riemser Pharma GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Riemser Pharma Acquires European Rights to Prialt from Eisai 12

Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13

RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14

Ardian May Sell Riemser Pharma for USD494.3 Million 15

AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17

Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19

Riemser Pharma to Acquire Intrapharm Labs 20

Riemser Pharma Acquires Keocyt 21

Riemser Arzneimittel To Acquire 49% Stake In anwerina 22

Riemser Pharma GmbH, Key Competitors 23

Riemser Pharma GmbH, Key Employees 24

Riemser Pharma GmbH, Other Locations 25

Riemser Pharma GmbH, Subsidiaries 25

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Riemser Pharma GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Riemser Pharma GmbH (Riemser), formerly Riemser Arzneimittel AG is a distributor of lifecycle management products. The company offers analgesics products, cardiovascular products, over-the-counter medicines, prescription drugs and dental products. It provides medical products for the treatment of infectious diseases, obesity, rheumatology, tuberculosis therapy, neurology, oncology and dermatological disorders such as psoriasis, acromycosis, acne, and herpes. Riemser also offers nutritional supplements. The company has research and development alliances with research institutes, universities, colleges and hospitals across Europe. It has operations in Germany, France and the UK. Riemser is headquartered in Greifswald, Germany.

Riemser Pharma GmbH-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 4

List of Figures 4

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details 12

Asset Purchase 12

Riemser Pharma Acquires European Rights to Prialt from Eisai 12

Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13

RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14

Private Equity 15

Ardian May Sell Riemser Pharma for USD494.3 Million 15

AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17

Asset Transactions 19

Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19

Acquisition 20

Riemser Pharma to Acquire Intrapharm Labs 20

Riemser Pharma Acquires Keocyt 21

Riemser Arzneimittel To Acquire 49% Stake In anwerina 22

Riemser Pharma GmbH-Key Competitors 23

Riemser Pharma GmbH-Key Employees 24

Riemser Pharma GmbH-Locations And Subsidiaries 25

Head Office 25

Other Locations & Subsidiaries 25

Appendix 26

Methodology 26

About GlobalData 26

Contact Us 26

Disclaimer 26


List Of Figure

List of Figures

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10


List Of Table

List of Tables

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Key Facts 2

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5

Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7

Riemser Pharma GmbH, Deals By Therapy Area, 2012 to YTD 2018 8

Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10

Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Riemser Pharma Acquires European Rights to Prialt from Eisai 12

Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13

RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14

Ardian May Sell Riemser Pharma for USD494.3 Million 15

AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17

Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19

Riemser Pharma to Acquire Intrapharm Labs 20

Riemser Pharma Acquires Keocyt 21

Riemser Arzneimittel To Acquire 49% Stake In anwerina 22

Riemser Pharma GmbH, Key Competitors 23

Riemser Pharma GmbH, Key Employees 24

Riemser Pharma GmbH, Other Locations 25

Riemser Pharma GmbH, Subsidiaries 25

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Riemser Pharma GmbH, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.